Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247012 | 0.81 | ALDH1A1 (0.50) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL22057007 | 0.79 | MAPT (0.53) | CA2CA1CA9CA12MAPT | |
| SCHEMBL5745307 | 0.79 | GAA (0.55) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL2320786 | 0.79 | PSEN1 (0.46) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL1169954 | 0.79 | ALDH1A1 (0.55) | CA2CA1TP53CA9CA12 | |
| SCHEMBL4074745 | 0.79 | ENPP2 (0.45) | TP53GLA | |
| SCHEMBL3195077 | 0.79 | PLCG1 (0.59) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL751 | 0.78 | PSIP1 (0.54) | CA2CA1TP53CA9CA12 | |
| Methane SCHEMBL8122177 | 0.77 | PSIP1 (0.52) | CA2CA1TP53CA9CA12 | |
| SCHEMBL7118736 | 0.76 | CA2 (0.52) | CA2CA1TP53CA12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
| EP-0941994-B1 | Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity | HOFFMANN LA ROCHE (CH) | 2003-05-14 | — | — | EP | disclosed |
| US-6194410-B1 | ANTISEROTONINE AGENTS; NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | HOFFMAN-LA ROCHE INC. | 2001-02-27 | — | — | US | disclosed |
| CN-1236780-A | Pyrazolopyrimidines and pyrazolotriazines | HOFFMANN LA ROCHE (CH) | 1999-12-01 | — | — | CN | disclosed |
| EP-0941994-A1 | Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128662-A1 | Novel compounds for treatment of obesity | GPR119, FABP4, HSD17B4 | F2 4369/4885PRSS1 835/4885PRSS2 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.